Andrew Oldham Email and Phone Number

• Allergist/Immunologist & ENT targeting withing multi-call points of Academic/Community Hospitals and Clinics• ENT Expanded Nucala®, indicated as an add-on, prescription maintenance treatment for chronic rhinosinusitis with nasal polyps • Allergy/Immunology promote Nucala for Severe Eosinophil Asthma, EGPA, and HES indications • IGNITE Pinnacle Award Q1 2024• IGNITE Torch Award - outstanding performance in passion & leadership. • IGNITE Fire Starter Award – outstanding knowledge & team initiation.

Launched Onlinvyk indicated for opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic to Anesthesiologist, Podiatrist & Surgeons in hospitals and surgical centers

Promote Nuzyra® (omadacycline) for Community-Acquired Pneumonia & Acute Bacterial Skin and Skin Structure Infections. Call points consisted of hospitals, Wound Care Centers, Infectious Disease, Podiatrist and Pulmonologist

Launched Xatmep (methotrexate Oral Solution) indicated for Pediatric ALL & Pediatric pJIA. Promote Qbrelis (lisinopril Oral Solution) and Epaned (enalapril Oral Solution) indicated for Pediatric Hypertension.

Launched Unituxin®, an anti-GD2 antibody indicated for high-risk Neuroblastoma. Covered multi-state calling on Children's Hospital to meet with Ped. Oncologist, Fellows, NP/PA, Nurses & Pharmacists to assist with the administration of Unituxin®. Presented high-level Unituxin® Clinical Educational In-service.

Launched Orenitram® , oral prostacyclin for PAH, as well as promoted Tyvaso®, Remodulin®. Responsible for detailing and educational in-service to Pulmonologist and Cardiologist.

A global biopharmaceutical company focused on the development and commercialization ofmedicines based on prostones.• Re-launch Rescula®,indicated for ocular-hypertension &glaucoma• Launched Amitiza®,indicated forChronic Idiopathic Constipation,IBS-C & OpioidInduced Constipation• Detailed & Preformed Clinical In-services on Ophthalmologists, Optometrist, LTCMedical Directors, LTC NP/PA, Primary Care Physicians with LTC interest & GI• Participating in Management Training Program• Additional Roles: Rep. Advisory Panel, Region Sales Trainer, MarketingAdvisory Team,iPad Salesforce Beta Tester

A pharmaceutical company engaged in the research, development and commercialization of products that target the hospital and neurology markets.- Promoted GLIADEL® Wafer, indicated for newly diagnosed high-grade glioma and recurrent GBM- Promote Aggrastat®, GPIIb/IIIa- Called on neurosurgeons, neuro-oncologist, oncologist, cardiologist, hospital pharmacies & Cath Lab staff- Regularly attended OR Gliadel® cases with neurosurgeons & Hospital Tumor Board - In-serviced hospital OR & ER/Cath Lab staff on handling Gliadel® cases & Aggrastat- Achievements: • 1Q2005 Gliadel Wafer – 100% of Goal • 1Q2005 Aggrastat – 195% of Goal (Ranked #2 overall)) • 2Q2005 Aggrastat – 74% of Goal (Ranked #7 overall) • #2 Ranked – 2004 Gliadel Wafer Sales Performance(120%) • 1Q2004 Highest Gliadel Quarterly Award • 3Q2004 Highest Gliadel Quarterly Award • 2002 Area of the Year Award

A Biomedical company that provides comprehensive personalized cancer management information to the oncologist and customized pre-clinical drug testing services to the biopharmaceutical community- Promoted ChemoFx®, an in-vitro chemotherapy resistance & sensitivity assay used to gather prospective responses on a patient’s specific cancer, in the state of Tennessee - Handled strategic complex sells involving oncologist, GYN oncologist, pathologist, surgeons & OR nurses.- Attended OR tumor biopsy cases with surgeons and worked with pathologist for appropriate specimen handling for ChemoFx® testing.

An innovative pharmaceutical company focusing on specialty pharmaceuticals in primary care, cardiology & GI- Launched Verelan PM® (controlled-onset release of veramapil) – CCB- Launched NuLev® (hyoscyamine sulfate orally disintegrating tablet)- Launched Colyte with Flavor Packs- Promote Univasc®/Uniretic® (moexipril) –ACE- Promoted Urso® (ursodiol) – indicated for PBC - Called on Family Practitioners, Internal Medicine, GI and Cardiologists- Achievements: • 1Q2000 Ranking: 85 of 255 (Territory ranked prior to hiring:143) • 2Q2000 Ranking: 46 of 255 • 3Q2000 Ranking: 44 of 255 • 4Q2000 Ranking: 57 of 255 • 1Q2001 Ranking: 55 of 255

A cancer research/services biotech company specializing in cryopreserving tumor specimens, creating autologous vaccines and T-lymphocytes expansion with IL-2 for treatment- National sales/marketing rep.: 600 clients - Outside sales to Middle Tennessee oncologists- Insurance/patient billing and reimbursement for laboratory services- Attended Cancer Biotherapy Research Group & American Society of Clinical Oncology meetings- Achievements: • 1998 - 14% increase in tumor service referrals • 1997 - 26% increase in tumor service referrals • 1996 - 13% increase in tumor service referrals

A glossy bi-monthly cancer magazine focusing on current news, research and treatments for oncologists, oncology nurses and cancer social workers - Co-founder of re-entry magazine- National advertising sales: 1100 Clients- Created/implemented pharmaceutical advertising programs- Involved in decision making for editorial content- Involved in magazine design - Regularly attended American Society of Clinical Oncology (ASCO) meetings